Melissa Rainey, APRN
Family · Charleston, WVNPI 1689235798
Payments from drug & device makers
Across 425 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Novartis$544
- Lilly USA, LLC$391
- Amgen$376
- AstraZeneca$330
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,694100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 141 | $1,725 |
| AbbVie | 70 | $1,351 |
| Novartis | 31 | $544 |
| Lilly USA, LLC | 24 | $391 |
| Amgen | 27 | $376 |
| AstraZeneca | 21 | $330 |
| Astellas Pharma US Inc | 8 | $181 |
| Bayer | 10 | $170 |
| Merck | 8 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $140 |
| Dexcom, Inc. | 7 | $139 |
| Pfizer | 7 | $124 |
| Biohaven Pharmaceuticals, Inc. | 7 | $120 |
| Amarin Pharma, Inc. | 7 | $118 |
| Sanofi-aventis U.S. LLC | 7 | $112 |
| Teva Pharmaceuticals USA, Inc. | 7 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $83 |
| GSK | 5 | $72 |
| Exact Sciences | 4 | $71 |
| Shield Therapeutics Inc | 2 | $43 |
| Optinose US, Inc. | 2 | $39 |
| Lexicon Pharmaceuticals, Inc. | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
| Tonix Medicines, Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Heartflow, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$6,694 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $85,294 |
| RexultiBrexpiprazole | 15 | $38,934 |
| EliquisApixaban | 36 | $38,466 |
| JardianceEmpagliflozin | 26 | $33,058 |
| MounjaroTirzepatide | 11 | $13,434 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,371 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $5,428 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $3,765 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,756 |
| Metoprolol Succinate | 94 | $1,801 |
| Levothyroxine Sodium | 130 | $1,396 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,183 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $1,066 |
| Gabapentin | 63 | $975 |
| Potassium Chloride | 26 | $794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,725 | $85,29446 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16 | $38,93415 claims |
| PfizerEliquis | $124 | $38,46636 claims |
| Lilly USA, LLCMounjaro | $391 | $13,43411 claims |
| GSKTrelegy Ellipta | $72 | $11,37112 claims |
| AbbVieSynthroid | $1,351 | $69017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Charleston
- Ashley ComerCharleston$213K
- Sarah KnightCharleston$99K
- Angela SettleCharleston$51K
- Malea SmithCharleston$13K
- Michelle MurrayCharleston$13K
- Kara DravenstottCharleston$11K
- Stacy RichardsonCharleston$11K
- Rebecca ButcherCharleston$9K
- Jade LewisCharleston$8K
- Ashton HolbrookCharleston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.